The Science
Understanding the Constellation
The conditions in this constellation aren't separate problems that happen to coexist. They share underlying mechanisms, biological processes that connect them at the root. You may have also heard this overlap called the trifecta. It is the same pattern, named in the shorthand many patients and clinicians use. Understanding those mechanisms doesn't require a medical degree. It requires a map.
Mechanism One
Autonomic
Dysregulation
When the nervous system that runs your body automatically loses its calibration
What It Is
Your autonomic nervous system controls everything your body does without your conscious direction: heart rate, blood pressure, digestion, temperature regulation, breathing, sweating. It runs continuously in the background, adjusting constantly to keep your internal environment stable. In autonomic dysregulation, this system loses its ability to respond appropriately. It overreacts where it should be quiet. It underreacts where it should activate. It responds at the wrong time, in the wrong direction, or with the wrong intensity.
The most recognized form in this cluster is POTS (Postural Orthostatic Tachycardia Syndrome). In POTS, the simple act of standing up becomes a physiological challenge the body cannot smoothly manage. Instead of the normal modest tachycardia that accompanies standing, the heart races dramatically, compensating for a failure to adequately redirect blood upward against gravity. The result is dizziness, palpitations, brain fog, nausea, and in severe cases, syncope. What feels like a cardiovascular problem is fundamentally a nervous system coordination failure.
Dysautonomia, the broader category, encompasses POTS and related conditions including orthostatic hypotension, neurocardiogenic syncope, and inappropriate sinus tachycardia. These share the underlying theme: the autonomic nervous system is not regulating as it should.
Common Symptoms
Who It Affects
POTS is estimated to affect one to three million Americans, with approximately 80% of patients being women, typically between ages 15 and 50. It frequently follows a triggering event such as viral illness, pregnancy, surgery, or significant physical trauma, though some patients have no identifiable trigger. The condition is substantially underdiagnosed, with many patients waiting years for recognition.
Conditions of Autonomic Dysregulation
POTS · Secondary POTS · Autoimmune POTS · Dysautonomia · Orthostatic Hypotension · Neurocardiogenic Syncope · Inappropriate Sinus Tachycardia · Small Fiber Neuropathy · Long COVID / PASC · Gastroparesis · ME/CFS · Sjogren's Syndrome
How It's Diagnosed
- Tilt table test: heart rate and blood pressure monitored while tilted from horizontal to standing
- NASA lean test: a lower-technology alternative measuring the same response
- Active stand test: bedside measurements at 2, 5, and 10 minutes of standing
- Diagnostic threshold: heart rate increase of ≥30 bpm (≥40 in adolescents) within 10 minutes of standing, without orthostatic hypotension
- 24-hour Holter monitoring, autonomic function testing in complex cases
Current Treatment Approaches
- Increased salt and fluid intake to expand blood volume (lifestyle)
- Compression garments to reduce venous pooling (OTC)
- Beta blockers (propranolol) to reduce heart rate response (prescription)
- Fludrocortisone to increase fluid retention (prescription)
- Midodrine to increase vascular tone (prescription)
- Ivabradine for heart rate reduction without affecting blood pressure (prescription)
- Graded exercise reconditioning, beginning recumbent (lifestyle / physical therapy)
- Identifying and treating underlying MCAS or connective tissue contributions
How autonomic dysregulation links to the other mechanisms
- Connective tissue laxity allows blood vessels to distend and pool blood more easily when upright, directly worsening orthostatic intolerance and driving the compensatory tachycardia in POTS.
- Mast cell mediators, including histamine and prostaglandins, can directly stimulate autonomic nerve fibers, trigger vasodilation, and worsen heart rate instability. Many POTS patients improve with antihistamines, pointing to this link.
- Neurological sensitization amplifies the perception of autonomic symptoms (dizziness feels more severe, fatigue more profound) and contributes to the migraine that frequently accompanies dysautonomia flares.
Key Research
- 2025 Epidemiology of Postural Orthostatic Tachycardia Syndrome: prevalence, demographics, and triggering events including viral illness and pregnancy. Mayo Clinic Proceedings. Mayo Proceedings →
- 2024 Theoharides et al. Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation. Annals of Allergy, Asthma & Immunology. Full text →
- 2023 Blitshteyn S. Dysautonomia, Hypermobility Spectrum Disorders and Mast Cell Activation Syndrome as Migraine Comorbidities. Current Neurology and Neuroscience Reports. PubMed →
- 2021 Vernino, Raj, Bourne, Stiles, Grubb, Fedorowski et al. POTS: State of the Science and Clinical Care from a 2019 NIH Expert Consensus Meeting (Part 1). Defines the ≥30 bpm (≥40 in adolescents) diagnostic threshold and current clinical care framework. Autonomic Neuroscience. Read the paper →
Mechanism Two
Mast Cell &
Immune Reactivity
When immune cells throughout your body activate too easily, too often, and with too much force
What It Is
Mast cells are immune cells positioned at every interface between your body and the outside world: in your skin, gut lining, airways, mucosal surfaces, connective tissue, and near nerve endings. They act as sentinels, releasing chemical mediators (histamine, tryptase, prostaglandins, leukotrienes, and many others) in response to threats. In a healthy system, this release is calibrated, targeted, and self-limiting. When it isn't, the result is mast cell activation: mediator release that is too frequent, too broad, or out of proportion to the trigger.
Mast cell activation exists on a spectrum. At the milder end, mast cell activation (MCA) may be limited to one body system or may not reach the severity threshold for a formal syndrome diagnosis. Many people in this community experience real, recurring mast cell symptoms (flushing, food reactions, skin sensitivity, GI distress) that fall into this category. At the severe end, when symptoms are recurrent, involve two or more organ systems, and can be linked to mast cell mediators through lab testing, the condition meets criteria for Mast Cell Activation Syndrome (MCAS). The distinction matters clinically, but the underlying biology is the same: mast cells releasing mediators they should not be releasing, or releasing them in quantities the body cannot manage.
What makes MCAS particularly elusive is that it operates through a different immune pathway than conventional allergies. Standard allergy tests measure IgE-mediated responses. MCAS involves multiple additional pathways those tests don't capture. A person can test negative for every known allergen and still be experiencing genuine, severe mast cell-driven reactions throughout their body simultaneously.
Because mast cells reside in virtually every organ system, MCAS can present as almost any combination of symptoms in almost any location, which is why patients are frequently seen by multiple specialists without anyone connecting the picture. The pattern, across systems and over time, is the diagnosis.
Common Symptoms
Histamine & The Thyroid
Emerging research has identified a statistically significant higher prevalence of thyroid cancer in women with MCAS compared to the general population. The relationship appears bidirectional: mast cells can store and release thyroid hormones, while thyroid antibodies can bind to mast cells and trigger their activation. Anyone with thyroid history, including nodules, Hashimoto's, or thyroid cancer, should discuss this emerging connection with their physician.
Root Causes & Drivers of MCAS
MCAS rarely arises from a single cause. Dr. Lawrence Afrin and others working in the field have identified seven categories of drivers that can trigger and sustain mast cell hyperreactivity, often layered together in any given patient. Identifying which apply to you is frequently the difference between symptom suppression and durable improvement: treating drivers shifts the underlying terrain rather than just quieting the alarm.
Genetic Predisposition
Some people inherit a heightened susceptibility to mast cell hyperreactivity. The most established drivers include KIT D816V (a somatic mutation that defines systemic mastocytosis and appears in a subset of MCAS), Hereditary Alpha Tryptasemia (extra copies of the TPSAB1 gene producing chronically elevated tryptase, now also associated with dysautonomia, chronic pain, and joint hypermobility, which places it squarely at the intersection of this constellation), and the RCCX Complex (a region of chromosome 6 linking immune, hormonal, and connective tissue dysregulation). Genetic testing is increasingly accessible when a hereditary pattern is suspected.
Chronic Infections
Persistent infections place ongoing demand on the immune system, and mast cells are direct participants in pathogen response. Pathogens repeatedly implicated as MCAS drivers include Lyme disease (and its co-infections), Epstein-Barr virus, mold and mycotoxin exposure, and chronic Candida overgrowth. In some patients, MCAS symptoms emerged or sharply worsened after an acute infection that was never fully cleared, including more recently after acute COVID-19.
Environmental Toxins
Chemicals in the modern environment can directly destabilize mast cells or place sustained burden on the body's detoxification systems. Frequently cited contributors include heavy metals (lead, mercury, arsenic), pesticides and herbicides, mold-derived mycotoxins, and endocrine-disrupting chemicals such as BPA, phthalates, and parabens common in plastics, cosmetics, and food packaging. Reducing exposure where feasible is one of the few interventions a patient can begin without prescription.
Gut Dysbiosis & Leaky Gut
The gut houses a substantial portion of the body's mast cells and shares its lining with trillions of microbes whose balance directly influences immune signaling. SIBO (small intestinal bacterial overgrowth), broader dysbiosis, and increased intestinal permeability (leaky gut) allow incompletely digested proteins and bacterial fragments to reach the bloodstream, triggering mast cells systemically. Restoring gut integrity is often a foundational step in stabilizing MCAS.
Hormonal Imbalances
Sex hormones modulate mast cell behavior with notable directionality. Estrogen upregulates mast cell activation, while progesterone tends to stabilize them. This explains the cyclical worsening many patients experience around ovulation and menstruation, the symptom amplification of perimenopause, and why pregnancy can either dramatically calm or dramatically worsen MCAS depending on hormonal balance. Thyroid dysfunction, particularly Hashimoto's thyroiditis, is another hormonal driver with documented bidirectional effects on mast cells.
Nervous System Dysregulation
Mast cells are densely concentrated near nerve endings and are direct partners of the autonomic nervous system. Chronic sympathetic activation (the "fight-or-flight" state), including from POTS, chronic stress, or unprocessed trauma, releases neuropeptides that trigger mast cell degranulation. This is why MCAS often worsens in periods of overwhelm and improves with nervous system regulation. The connection between trauma and mast cell biology is explored in the work of Dr. Gabor Maté and others.
Autoimmune Disorders
Autoimmune conditions and MCAS frequently coexist, with each capable of driving the other. Conditions documented in MCAS comorbidity include Hashimoto's thyroiditis, Sjogren's syndrome, lupus, and rheumatoid arthritis. The shared mechanism appears to involve chronic immune activation and the production of autoantibodies that can bind to mast cells and trigger their release. Identifying and treating an underlying autoimmune driver often improves MCAS stability significantly.
Most patients have more than one driver active. Working with a knowledgeable physician to identify which of these seven categories apply, and addressing them methodically, is what shifts MCAS from a chronic crisis to a manageable condition. The framework is the map. Your specific drivers are the route.
Classification: Three Types of MCAS
When MCAS is confirmed, the next question is what is driving it. An international consensus group classifies MCAS into three categories based on the underlying cause:
Primary (clonal) MCAS means the mast cells themselves carry a genetic mutation, most often KIT D816V. These patients may have an underlying clonal mast cell disease such as systemic mastocytosis. This is the rarest form and is identified through bone marrow biopsy and molecular testing.
Secondary MCAS means the mast cells are structurally normal but are being activated by an identifiable external driver: an IgE-dependent allergy, a chronic infection, an autoimmune condition, or another reactive process. Most patients in this community who meet MCAS criteria fall into this category or the next one.
Idiopathic MCAS means the criteria for MCAS are met, but no clonal mast cell disease and no clear external driver has been identified. The mast cells are misbehaving, and the reason is not yet known. This is a legitimate diagnosis, not a dead end. It simply means the search for the underlying driver continues.
These categories are not mutually exclusive. A patient can have both primary and secondary MCAS (for example, mastocytosis plus a bee venom allergy), which compounds the risk substantially. Understanding which category applies shapes the treatment approach: primary MCAS may require targeted therapies against mutant mast cells, secondary MCAS benefits from treating the underlying trigger, and idiopathic MCAS is managed with broad mast cell stabilization while the search for drivers continues.
Two Diagnostic Frameworks
If you research MCAS, you will encounter two major diagnostic frameworks that do not fully agree. Understanding the difference helps you make sense of what your doctor tells you and why different clinicians may reach different conclusions from the same evidence.
The consensus criteria (Valent, Akin, and colleagues) define MCAS strictly: recurrent severe systemic episodes (often with anaphylaxis), a documented event-related rise in serum tryptase above the patient's baseline, and response to mast cell-directed treatment. All three criteria must be met. Under this framework, chronic symptoms without episodic severe attacks and without a measurable tryptase spike do not qualify as MCAS, though they may represent clinically meaningful MCA.
The broader criteria (Afrin, Weinstock, and colleagues, sometimes called "Consensus-2") recognize that tryptase is not the only relevant mediator, that mast cell activation can be chronic rather than purely episodic, and that many patients with genuine mast cell-driven illness never show a tryptase spike because their reactions operate through non-tryptase pathways. This framework accepts a wider range of mediator evidence and clinical presentations.
Neither framework is wrong. They represent different positions on where to draw a diagnostic line in a condition that medicine is still learning to characterize. The stricter criteria reduce the risk of misdiagnosis; the broader criteria reduce the risk of patients with real mast cell disease being told nothing is wrong. If your doctor says you don't have MCAS, it may mean you don't meet the stricter criteria, not that your symptoms lack a biological basis. If another doctor says you do, they may be applying the broader framework. Both positions are held by credentialed researchers publishing in peer-reviewed journals. What matters most is that your symptoms are taken seriously and investigated thoroughly regardless of which label applies.
Disorders of Mast Cells & Immune Reactivity
Mast Cell Activation (MCA) · MCAS · Mast Cell Activation Disorder · Mastocytosis · Hereditary Alpha Tryptasemia · Idiopathic Anaphylaxis · Histamine Intolerance · Chronic Urticaria · Eosinophilic Esophagitis · IBS · SIBO · Endometriosis · Interstitial Cystitis / Bladder Pain Syndrome · Vulvodynia · Dysmenorrhea · PMDD · PCOS · Uterine Fibroids · Hashimoto's Thyroiditis · Lupus · Rheumatoid Arthritis · Lyme Disease
How It's Diagnosed
- Clinical diagnosis: recurrent multisystem symptoms consistent with mast cell mediator release
- Serum tryptase: an event-related rise of at least 20% above the individual's baseline plus 2 ng/mL, measured within 1 to 4 hours of a reaction (the "20%+2 formula")
- Urine N-methylhistamine, prostaglandin D2, prostaglandin F2-alpha, leukotriene E4
- Response to H1 and H2 antihistamines or mast cell stabilizers (therapeutic trial)
- Tissue biopsy (skin, GI) showing elevated mast cells in selected cases
- Two major diagnostic frameworks exist and do not fully agree on criteria. A negative evaluation under one framework does not rule out clinically meaningful mast cell activation.
Current Treatment Approaches
- H1 antihistamines: cetirizine, loratadine (OTC); diphenhydramine (OTC); hydroxyzine (prescription)
- H2 antihistamines: famotidine (OTC) to address different receptor populations
- Mast cell stabilizers: cromolyn sodium oral (OTC / prescription depending on formulation); ketotifen (prescription in US)
- DAO enzyme supplementation to support histamine breakdown (OTC)
- Low-histamine diet and trigger identification (lifestyle)
- Low-dose aspirin in prostaglandin-dominant presentations, physician-guided (OTC, but requires medical supervision in this context)
- Leukotriene inhibitors: montelukast in some presentations (prescription)
- Addressing hormonal fluctuations that worsen mast cell reactivity (physician-guided)
How mast cell reactivity links to the other mechanisms
- Connective tissue is where mast cells live. Disrupted collagen in HSD/hEDS alters the tissue environment of mast cells, potentially destabilizing them and causing them to activate more readily. Up to 25% of hEDS patients are estimated to also have MCAS.
- Autonomic dysregulation and mast cell activation are bidirectional. The autonomic nervous system can trigger mast cell degranulation; mast cell mediators can stimulate autonomic nerve fibers. Many POTS patients find their tachycardia and flushing episodes are substantially improved by antihistamines.
- Neurological sensitization is amplified by mast cell mediators. Histamine directly lowers pain thresholds and is one of the most potent known migraine triggers. Mast cells located near nerve endings release substances that sensitize pain pathways and contribute to the central sensitization underlying chronic migraine.
- Chronic itch arises from this same mast cell and nerve partnership. Mast cells release histamine and nerve growth factor that sensitize nearby sensory nerves, producing itch that outlasts any rash and can be triggered by ordinary warmth or touch. See Itch as Sensitization under Neurological Sensitization.
Key Research
- 2024 Quigley, Noble, Ansari. The Suggested Relationships Between Common GI Symptoms and Joint Hypermobility, POTS, and MCAS. Gastroenterology & Hepatology. Read the paper →
- 2022 Association of mast-cell-related conditions with hypermobile syndromes: review of disrupted collagen and its effect on resident mast cells. Read the paper →
- 2021 Weinstock, Brook, Walters, Goris, Afrin, Molderings. Mast cell activation symptoms are prevalent in Long-COVID. International Journal of Infectious Diseases. Read the paper →
- 2020 Afrin, Ackerley, Bluestein, Dempsey, Weinstock et al. Diagnosis of Mast Cell Activation Syndrome: A Global "Consensus-2", the diagnostic criteria framework establishing MCAS as distinct from IgE-mediated allergy. Diagnosis (Berlin). Read the paper →
- 2019 Valent P, Akin C, Bonadonna P, et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. Introduces the primary/secondary/idiopathic MCAS classification and stepwise diagnostic approach. J Allergy Clin Immunol Pract. Read the paper →
- 2019 Valent P, Akin C. Doctor, I Think I Am Suffering from MCAS: Differential Diagnosis and Separating Facts from Fiction. Establishes strict consensus criteria for MCAS diagnosis and differential diagnosis framework. J Allergy Clin Immunol Pract. Read the paper →
- 2019 Golden DBK. The Many Faces of Mast Cell Disorders: A House of Mirrors? Editorial overview of the overlap between mastocytosis, MCAS, idiopathic anaphylaxis, and alpha-tryptasemia. J Allergy Clin Immunol Pract. Read the paper →
- 2017 Afrin, Self, Menk, Lazarchick. Characterization of Mast Cell Activation Syndrome: the first systematic characterization of 413 MCAS patients, documenting demographics, comorbidities, symptoms, triggers, and family histories. American Journal of the Medical Sciences. Read the paper →
- 2017 Molderings et al. Risk of solid cancer in patients with mast cell activation syndrome: documents significantly elevated prevalence of thyroid cancer in women with MCAS compared to general population. F1000Research →
- 2016 Lyons et al. Elevated basal serum tryptase identifies a multisystem disorder associated with increased TPSAB1 copy number: the paper that discovered Hereditary Alpha Tryptasemia. Nature Genetics. Read the paper →
Mechanism Three
Connective Tissue &
Structural Disorders
When the body's scaffolding is systemically lax or fragile, affecting every structure it supports
What It Is
Connective tissue is the body's structural framework: collagen and related proteins that give form, elasticity, and integrity to joints, skin, blood vessel walls, gut lining, ligaments, tendons, and organs. When connective tissue is dysregulated, this scaffolding becomes lax or fragile throughout the body simultaneously. The effects are not limited to joints that bend too far. The same structural compromise affects blood vessels (contributing to orthostatic intolerance), gut walls (contributing to dysmotility and reflux), mucosal surfaces (contributing to fragility and inflammation), and the microenvironment where mast cells live.
Hypermobility Spectrum Disorder (HSD) and hypermobile Ehlers-Danlos Syndrome (hEDS) exist on a continuous spectrum, from generalized joint hypermobility with functional impairment through to hEDS with additional skin, autonomic, and systemic involvement. Neither condition has a confirmed genetic marker despite being heritable, which has historically made diagnosis difficult and contributed to decades of dismissal for many patients.
The Beighton score is the primary screening tool, but clinicians increasingly recognize that hypermobility's most disabling effects are often systemic rather than articular, and that a score alone captures only part of the picture.
Common Symptoms
The Gut Connection
Connective tissue is richly represented throughout the gastrointestinal system, including the gut wall, peritoneal ligaments, and splanchnic vessels. Research suggests that the same collagen dysregulation causing joint laxity extends to the gut, contributing directly to dysmotility, gastroparesis, reflux, and visceral hypersensitivity. The extracellular matrix also appears to influence the development of the enteric nervous system, creating a direct structural link between connective tissue health and GI neurological function.
Connective Tissue & Structural Disorders
HSD · hEDS · EDS · Marfan Syndrome · Loeys-Dietz Syndrome · Mitral Valve Prolapse · Raynaud's Phenomenon · Craniocervical Instability · Spontaneous CSF Leak · Tethered Cord Syndrome · Chiari Malformation · Cervicogenic Headache
How It's Diagnosed
- Beighton score: standardized assessment of joint hypermobility across 9 points
- Clinical criteria (2017 International Classification) for hEDS requires Beighton score plus additional systemic features
- HSD diagnosed when symptomatic hypermobility is present without meeting full hEDS criteria
- Physical examination of skin, joints, and connective tissue features
- Exclusion of other heritable connective tissue disorders
- Genetic testing not available for hEDS; diagnosis is clinical
Current Treatment Approaches
- Physical therapy focused on joint stabilization and proprioception (referral required)
- Occupational therapy for joint protection and activity modification (referral required)
- Pain management: acetaminophen or ibuprofen for mild pain (OTC); stronger options require prescription
- Bracing and orthotic supports for unstable joints (OTC / custom prescription orthotics)
- Treating comorbid POTS and MCAS: addressing systemic drivers (physician-guided)
- Pelvic floor physical therapy for genitourinary involvement (referral required)
- Avoiding high-impact activity and overextension (lifestyle)
How connective tissue dysregulation links to the other mechanisms
- Autonomic dysregulation: Lax blood vessel walls allow blood to pool in the lower body on standing, directly driving the compensatory tachycardia of POTS. Connective tissue laxity in the autonomic nervous system infrastructure may itself impair neural signaling.
- Mast cell reactivity: Mast cells reside within connective tissue. Disrupted collagen alters their microenvironment, causing them to activate aberrantly. Conversely, mast cell mediators including tryptase and histamine promote collagen production and fibroblast activity, creating a bidirectional interaction.
- Neurological sensitization: Chronic joint instability and the muscular overwork required to compensate for lax ligaments generates continuous nociceptive input, a sustained signal that feeds the central sensitization cycle and amplifies pain perception throughout the body.
Key Research
- 2024 Wu and Ho. An overview of Ehlers-Danlos Syndrome and the link between POTS and gastrointestinal symptoms with a focus on gastroparesis. Frontiers in Neurology. Full text →
- 2024 Quigley et al. The Suggested Relationships Between Common GI Symptoms and Joint Hypermobility, POTS, and MCAS: connective tissue and extracellular matrix mechanisms. Gastroenterology & Hepatology. Read the paper →
- 2020 Kucharik & Chang. The Relationship Between Hypermobile EDS, POTS, and Mast Cell Activation Syndrome: documents the up to ~25% comorbidity rate of MCAS in hEDS populations. Clinical Reviews in Allergy & Immunology. Read the paper →
- 2017 Miglis, Schultz, Muppidi. Postural tachycardia in hypermobile Ehlers-Danlos syndrome: A distinct subtype? Autonomic Neuroscience. Read the paper →
Mechanism Four
Neurological Sensitization
& Pain Processing
When the nervous system's volume dial gets turned up and cannot find its way back down
What It Is
Pain is a signal, not a measurement. Your nervous system normally amplifies pain when tissue is genuinely threatened, a useful alarm. In central sensitization, this amplification becomes chronic and self-sustaining, persisting long after any original injury or trigger has resolved. The nervous system turns up its own volume and cannot turn it back down. Inputs that shouldn't cause pain become painful. Pain that should be mild becomes severe. Sensory experiences that shouldn't be overwhelming, including light, sound, smell, touch, and vibration, become intolerable.
Migraine is the most recognized form of neurological sensitization in this cluster, and one of the most common comorbidities across POTS, MCAS, and HSD. The same mechanism also underlies widespread pain amplification, fibromyalgia (which co-occurs in over half of hEDS/HSD patients), the profound sensory hypersensitivities many patients experience, and much of what presents clinically as brain fog, a nervous system so sensitized that processing becomes inefficient. Central sensitization has been documented across fibromyalgia, osteoarthritis, EDS, headache, and spinal pain, with the same amplification mechanism driving pain across all of them.
Central sensitization is not psychological. It is a demonstrable neurophysiological state with measurable changes in spinal and cortical excitability, altered neurotransmitter balance, and neuroinflammatory markers. The persistent false narrative that these symptoms are anxiety or somatization has delayed appropriate treatment for many in this community by years or decades.
Common Symptoms
Migraine in This Cluster
Migraine is not simply a headache. It is a neurological disorder involving waves of cortical spreading depression, trigeminovascular activation, and profound central sensitization. In the context of MCAS, POTS, and HSD, migraine is both more frequent and more treatment-resistant because the upstream drivers (mast cell mediator release, autonomic instability, chronic nociceptive input from unstable joints) are not being addressed. In patients with MCAS-migraine overlap, antihistamines have been shown to address the histamine-driven mechanism when triptans have not provided adequate relief — a clinical signal pointing toward histamine-mediated triggering rather than purely vascular mechanisms.
Sensitization Beyond Pain
Pain is the most studied expression of central sensitization, but it is not the only one. The same amplification shows up in other channels, which is why several conditions in this cluster share its mechanism.
Fibromyalgia is central sensitization in its purest form: widespread pain without a wound, fatigue without exertion, and the cognitive fog patients call "fibro fog." It is often described as the second most common rheumatic condition after osteoarthritis, and it co-occurs in more than half of people with hEDS or HSD. For decades it was dismissed as pain with no physical basis, a judgment that did real harm. The research now says otherwise in two directions at once: centrally, measurable changes in how the brain and spinal cord process pain; peripherally, roughly half of patients have demonstrable small-fiber pathology, replicated across independent meta-analyses. For many, then, a real peripheral signal feeds the central amplification, not an imagined one. It is a clear example of nociplastic pain: pain that is real and legitimate even when scans and blood tests look normal.
Chronic itch follows the same rules in a different channel. The vocabulary mirrors pain almost exactly: itch has alloknesis (itch from a stimulus that should not itch, like fabric against skin) and hyperknesis (a small itch magnified into an overwhelming one), the itch-world counterparts of allodynia and hyperalgesia. These are measurable states, not metaphors, which is why itch here can persist long after a rash fades and can be triggered by ordinary warmth or touch. It begins at the mast cell: skin mast cells beside sensory nerve endings release histamine, tryptase, and nerve growth factor that sensitize the nerves, while the nerves release substances that re-activate the mast cells, a self-sustaining loop. This is the same mast cell partnership described in the mast cell section, seen from the angle of itch, and it is why antihistamines sometimes only go part of the way. The sensitization is documented at both the nerve and the spinal and brain levels.
Heightened senses complete the picture. In a sensitized nervous system, light, sound, smell, and touch can all become too much at once, the symptoms listed above as photophobia, phonophobia, and the rest. They are not separate problems but one phenomenon, multisensory hypersensitivity. The same sensitized processing that amplifies pain appears to amplify other sensory input through shared brain hubs, the insula chief among them. In migraine, where it is best studied, each sensitivity affects a majority of patients and many experience two or three together, with greater burden meaning greater disability. For anyone told they are simply "too sensitive," recognizing many sensitivities as one sensitized system is often a quiet relief, and a reason to treat protecting your sensory environment as legitimate symptom management.
Conditions of Neurological Sensitization
Migraine · Vestibular Migraine · Fibromyalgia · Central Sensitization Syndrome · CRPS · NDPH · Occipital Neuralgia · TMD · Medication Overuse Headache · ME/CFS · Small Fiber Neuropathy · Cervicogenic Headache
How It's Diagnosed
- Clinical diagnosis based on symptom pattern. No single test confirms central sensitization.
- Central Sensitization Inventory (CSI): a validated self-report screening tool
- Migraine: International Headache Society diagnostic criteria
- Quantitative sensory testing in research settings
- Exclusion of structural causes of pain
- Pattern recognition across systems: widespread hypersensitivity alongside other cluster diagnoses
Current Treatment Approaches
- CGRP antagonists (gepants and monoclonal antibodies) for migraine prevention and acute treatment (prescription)
- Triptans for acute migraine (prescription)
- Antihistamines, particularly when histamine is a migraine trigger: cetirizine, loratadine (OTC); hydroxyzine (prescription)
- Low-dose tricyclic antidepressants: amitriptyline for central sensitization and sleep (prescription)
- SNRIs: duloxetine for pain amplification (prescription)
- Anticonvulsants: gabapentin, pregabalin for neuropathic pain (prescription)
- Pain psychology and mindfulness-based approaches (referral / self-directed)
- Addressing upstream drivers: treating MCAS, improving autonomic function (physician-guided)
How neurological sensitization links to the other mechanisms
- Mast cell mediators are directly neurosensitizing. Histamine lowers pain thresholds and is one of the most potent known migraine triggers. Mast cells positioned near nerve endings release substances that amplify neural excitability, feeding central sensitization from the periphery inward.
- Autonomic dysregulation contributes to the neurological cascade underlying migraine through vascular instability and impaired cerebral blood flow regulation. Migraine attacks are frequently triggered or worsened by the same orthostatic stressors that trigger POTS symptoms.
- Connective tissue instability generates continuous peripheral nociceptive input from unstable, overworked joints, providing the sustained signal that maintains and amplifies central sensitization over time. Treating joint instability can reduce the upstream driver of chronic pain.
Key Research
- 2021 Kataoka H et al. Investigating the relationships between the burden of multiple sensory hypersensitivity symptoms and headache-related disability in patients with migraine. Found photophobia, phonophobia, and osmophobia in 75%, 77%, and 55% of patients, frequently coexisting, with greater burden tracking greater disability. The Journal of Headache and Pain. Read the paper →
- 2018 Andersen HH, Akiyama T, Nattkemper LA et al. Alloknesis and hyperknesis: mechanisms, assessment methodology, and clinical implications of itch sensitization. Establishes that chronic itch sensitizes the nervous system the way pain does, with alloknesis and hyperknesis mirroring allodynia and hyperalgesia. Pain. Read the paper →
- 2025 Li D, Han Y, Zhou J et al. Mast cell–neuron axis as a core mechanism in chronic pruritus. Describes the self-sustaining loop in which skin mast cells sensitize sensory nerves and the nerves reactivate the mast cells, linking immune activation directly to itch. Frontiers in Immunology. Read the paper →
- 2023 Itch: from the skin to the brain, peripheral and central neural sensitization in chronic itch. Reviews how chronic itch is sustained by sensitization at both the nerve and spinal/brain levels, often persisting after visible inflammation resolves. Frontiers in Molecular Neuroscience. Read the paper →
- 2019 Grayston R, Czanner G, Elhadd K et al. A systematic review and meta-analysis of the prevalence of small fiber pathology in fibromyalgia. Found small-fiber pathology in roughly half of fibromyalgia patients (pooled prevalence 49%), evidence of a peripheral component feeding central amplification. Seminars in Arthritis and Rheumatism. Read the paper →
- 2018 Harte SE, Harris RE, Clauw DJ. The neurobiology of central sensitization. Positions fibromyalgia as the prototype central sensitization condition and describes multisensory hypersensitivity as a core feature. Journal of Applied Biobehavioral Research. Read the paper →
- 2023 Blitshteyn S. Dysautonomia, HSD, and MCAS as Migraine Comorbidities: first peer-reviewed review of this triad in the context of migraine. PubMed →
- 2023 Fairweather D, Bruno KA, Darakjian AA et al. High overlap in patients diagnosed with hEDS/HSD with fibromyalgia and 40 self-reported symptoms and comorbidities. Of 733 patients at an EDS clinic, 56.5% had both hEDS/HSD and fibromyalgia. Frontiers in Medicine. Read the paper →
- 2022 Central Sensitization in Migraine: A Narrative Review, mechanisms of cortical sensitization and their relationship to fibromyalgia and chronic fatigue. Read the paper →
- 2021 Central Sensitization in Neurological, Psychiatric, and Pain Disorders: multicenter case-controlled study showing shared sensitization mechanisms across migraine, IBS, fibromyalgia, and related conditions. Documents measurable changes in spinal and cortical excitability. Read the paper →
- 2021 Nijs J, George SZ, Clauw DJ et al. Central sensitisation in chronic pain conditions: latest discoveries and their potential for precision medicine. Documents central sensitization across fibromyalgia, osteoarthritis, EDS, headache, and spinal pain. The Lancet Rheumatology. Read the paper →
- 2021 Dong H, Zhang X, Qian Y. Mast cells and neuroinflammation in the pathophysiology of pain: mast cell degranulation creates a positive feedback loop of peripheral and central sensitization leading to chronic pain. Frontiers in Cellular Neuroscience. Read the paper →
- 2019 Theoharides TC, Tsilioni I, Bawazeer M. Mast Cells, Neuroinflammation and Pain in Fibromyalgia Syndrome. Proposes thalamic mast cells contribute to fibromyalgia pain through release of histamine, IL-6, TNF, CGRP, and substance P. Frontiers in Cellular Neuroscience. Read the paper →
The Bigger Picture
How They Connect
These four mechanisms don't operate in isolation. They are the points of a constellation: each one influences the others, and the picture only becomes legible when they are mapped together. Treating any single condition in isolation so often fails to resolve the full picture because the picture lives in the connections.
Autonomic Dysregulation drives Mast Cell Activation
The autonomic nervous system directly stimulates mast cells. When it's dysregulated, it can trigger inappropriate mast cell degranulation, flooding the body with histamine and other mediators even without an external trigger. This is why POTS patients often experience flushing, hives, and GI distress that respond to antihistamines.
Mast Cell Mediators destabilize the Autonomic System
Histamine, prostaglandins, and leukotrienes released by activated mast cells can directly stimulate autonomic nerve fibers, cause vasodilation, and worsen orthostatic intolerance. The relationship is bidirectional, each system amplifying dysregulation in the other.
Connective Tissue Laxity drives Autonomic Dysregulation
Lax blood vessel walls allow blood to pool in the lower body when upright, directly driving the compensatory tachycardia of POTS. This structural explanation accounts for why a substantial proportion of POTS patients have concurrent hypermobility. The mechanism is physical as well as neurological.
Disrupted Collagen destabilizes Mast Cells
Mast cells live within connective tissue. When that tissue is structurally abnormal, the microenvironment of mast cells changes, causing them to activate more readily without appropriate provocation. This may explain why up to 25% of hEDS patients also have MCAS.
Mast Cell Mediators fuel Neurological Sensitization
Histamine is one of the most potent known migraine triggers and directly lowers pain thresholds throughout the nervous system. Mast cells positioned near nerve endings release substances that sensitize pain pathways, providing continuous input that maintains and amplifies central sensitization.
Joint Instability feeds Pain Amplification
Unstable hypermobile joints generate continuous nociceptive input, with muscles working overtime to stabilize what ligaments should hold. This sustained peripheral signal feeds the central sensitization cycle, explaining why people with HSD often experience pain disproportionate to what imaging reveals.
"This is why treating one condition while ignoring the others so often provides incomplete relief. The mechanisms are interlocking. Reducing mast cell reactivity may calm autonomic instability. Stabilizing joints reduces peripheral pain input. Treating POTS improves cerebral blood flow and may reduce migraine frequency. Each intervention ripples through the system."
"The science is still catching up to the full picture. What is already clear is that these conditions share biology, and that the patients living at their intersection deserve care that treats the whole, not the parts."
Key Research
- 2024 Theoharides et al. Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation, a mechanistic review of how the four mechanisms interlock at the cellular level. Annals of Allergy, Asthma & Immunology. Full text →
- 2024 Quigley, Noble, Ansari. The Suggested Relationships Between Common GI Symptoms and Joint Hypermobility, POTS, and MCAS, a cross-mechanism review of how connective tissue, autonomic, and mast cell dysfunction converge in GI presentations. Gastroenterology & Hepatology. Read the paper →
- 2023 Blitshteyn S. Dysautonomia, HSD, and MCAS as Migraine Comorbidities, the first peer-reviewed review framing the four mechanisms as a connected triad. Current Neurology and Neuroscience Reports. PubMed →
For more key articles, check out my Research Library.
Recognize what you've read here in your own body?
You are not imagining it.